Cite
MLA Citation
John P. Gibbs et al.. “Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).” Journal of clinical pharmacology, vol. 57, 2017, pp. 616–626. http://access.bl.uk/ark:/81055/vdc_100045410882.0x000042